{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:57:40Z","timestamp":1794542260053,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7839","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,12,24]]},"DOI":"10.1038\/s41586-020-2911-7","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T12:02:50Z","timestamp":1605096170000},"page":"693-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":469,"title":["Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer"],"prefix":"10.1038","volume":"588","author":[{"given":"Xinjian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanman","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-6231","authenticated-orcid":false,"given":"Chuan-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"2911_CR1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"2911_CR4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"2911_CR5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"2911_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"key":"2911_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161\u2013165 (2005); corrigendum 37, 328 (2005).","journal-title":"Nat. Genet."},{"key":"2911_CR8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang, W. et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature 531, 651\u2013655 (2016).","journal-title":"Nature"},{"key":"2911_CR10","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1084\/jem.20171576","volume":"215","author":"X Ma","year":"2018","unstructured":"Ma, X. et al. Cholesterol negatively regulates IL-9-producing CD8+ T cell differentiation and antitumor activity. J. Exp. Med. 215, 1555\u20131569 (2018).","journal-title":"J. Exp. Med."},{"key":"2911_CR11","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1091\/mbc.e04-02-0151","volume":"15","author":"N Naslavsky","year":"2004","unstructured":"Naslavsky, N., Weigert, R. & Donaldson, J. G. Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol. Biol. Cell 15, 3542\u20133552 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"2911_CR12","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet, S. et al. NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865\u201348875 (2004).","journal-title":"J. Biol. Chem."},{"key":"2911_CR13","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","volume":"102","author":"KN Maxwell","year":"2005","unstructured":"Maxwell, K. N., Fisher, E. A. & Breslow, J. L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl Acad. Sci. USA 102, 2069\u20132074 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2911_CR14","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang, D. W. et al. Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602\u201318612 (2007).","journal-title":"J. Biol. Chem."},{"key":"2911_CR15","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","volume":"116","author":"TA Lagace","year":"2006","unstructured":"Lagace, T. A. et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116, 2995\u20133005 (2006).","journal-title":"J. Clin. Invest."},{"key":"2911_CR16","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier, S. et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J. Biol. Chem. 284, 28856\u201328864 (2009).","journal-title":"J. Biol. Chem."},{"key":"2911_CR17","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier, S. et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363\u20132372 (2008).","journal-title":"J. Biol. Chem."},{"key":"2911_CR18","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel, M. et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 8, e64145 (2013).","journal-title":"PLoS One"},{"key":"2911_CR19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","volume":"35","author":"A Demers","year":"2015","unstructured":"Demers, A. et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler. Thromb. Vasc. Biol. 35, 2517\u20132525 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2911_CR20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/embor.2008.132","volume":"9","author":"MC Jonas","year":"2008","unstructured":"Jonas, M. C., Costantini, C. & Puglielli, L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 9, 916\u2013922 (2008).","journal-title":"EMBO Rep."},{"key":"2911_CR21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom, D. J. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370, 1809\u20131819 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489\u20131499 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"2911_CR24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 2281\u20132308 (2013).","journal-title":"Nat. Protocols"},{"key":"2911_CR25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","volume":"92","author":"S Ishibashi","year":"1993","unstructured":"Ishibashi, S. et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883\u2013893 (1993).","journal-title":"J. Clin. Invest."},{"key":"2911_CR26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S K\u00fchnast","year":"2014","unstructured":"K\u00fchnast, S. et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res. 55, 2103\u20132112 (2014).","journal-title":"J. Lipid Res."},{"key":"2911_CR28","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"JC Chan","year":"2009","unstructured":"Chan, J. C. et al. A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106, 9820\u20139825 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2911_CR29","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2911_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-019-0614-0","volume":"7","author":"V Chandramohan","year":"2019","unstructured":"Chandramohan, V. et al. Improved efficacy against malignant brain tumors with EGFRwt\/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J. Immunother. Cancer 7, 142 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2911_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17\u201327 (1994).","journal-title":"Cell"},{"key":"2911_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","volume":"375","author":"L Shan","year":"2008","unstructured":"Shan, L. et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375, 69\u201373 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2911_CR33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2008.10.027","volume":"203","author":"T Fasano","year":"2009","unstructured":"Fasano, T., Sun, X. M., Patel, D. D. & Soutar, A. K. Degradation of LDLR protein mediated by \u2018gain of function\u2019 PCSK9 mutants in normal and ARH cells. Atherosclerosis 203, 166\u2013171 (2009).","journal-title":"Atherosclerosis"},{"key":"2911_CR34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","volume":"419","author":"CJ Duff","year":"2009","unstructured":"Duff, C. J. et al. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419, 577\u2013584 (2009).","journal-title":"Biochem. J."},{"key":"2911_CR35","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/intimm\/11.12.1897","volume":"11","author":"YY Yu","year":"1999","unstructured":"Yu, Y. Y. et al. Definition and transfer of a serological epitope specific for peptide-empty forms of MHC class I. Int. Immunol. 11, 1897\u20131906 (1999).","journal-title":"Int. Immunol."},{"key":"2911_CR36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2911_CR37","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens, J. L. et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat. Commun. 8, 15095 (2017).","journal-title":"Nat. Commun."},{"key":"2911_CR38","doi-asserted-by":"crossref","first-page":"W171","DOI":"10.1093\/nar\/gkz365","volume":"47","author":"K Labun","year":"2019","unstructured":"Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47 (W1), W171\u2013W174 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2911_CR39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"2911_CR40","first-page":"e51998","volume":"92","author":"S Borowicz","year":"2014","unstructured":"Borowicz, S. et al. The soft agar colony formation assay. J. Vis. Exp. 92, e51998 (2014).","journal-title":"J. Vis. Exp."},{"key":"2911_CR41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","volume":"54","author":"MW Moore","year":"1988","unstructured":"Moore, M. W., Carbone, F. R. & Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777\u2013785 (1988).","journal-title":"Cell"},{"key":"2911_CR42","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.4049\/jimmunol.160.7.3236","volume":"160","author":"JM Curtsinger","year":"1998","unstructured":"Curtsinger, J. M., Lins, D. C. & Mescher, M. F. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C\u2212) to TCR\/CD8 signaling in response to antigen. J. Immunol. 160, 3236\u20133243 (1998).","journal-title":"J. Immunol."},{"key":"2911_CR43","volume":"12","author":"SJ Park","year":"2019","unstructured":"Park, S. J., Yoon, B. H., Kim, S. K. & Kim, S. Y. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med. Genomics 12 (Suppl 5), 101 (2019).","journal-title":"BMC Med. Genomics"},{"key":"2911_CR44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"2911_CR45","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.6273er1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41586-020-2911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-020-2911-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41586-020-2911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:42:42Z","timestamp":1697064162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":45,"journal-issue":{"issue":"7839","published-print":{"date-parts":[[2020,12,24]]}},"alternative-id":["2911"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2911-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739014793.793581528","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.739014793.793585586","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"24 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.L. and C.-Y.L. are inventors on a patent application filed by Duke University that covers the use of anti-PCSK9 antibodies in cancer immunotherapy. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}